CompletedPhase 2NCT01525875
Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)
Studying Pseudoxanthoma elasticum
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mark Lebwohl
- Principal Investigator
- Mark Lebwohl, MDIcahn School of Medicine at Mount Sinai
- Intervention
- Magnesium Oxide(drug)
- Enrollment
- 44 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2015
Study locations (1)
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01525875 on ClinicalTrials.govOther trials for Pseudoxanthoma elasticum
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07323082Purinergic Compounds in Pseudoxanthoma ElasticumCentre Hospitalier Universitaire de Nice
- RECRUITINGNANCT07006649CHOPXE - Analysis of Choriocapillaris Flow Deficits in Patients With Pseudoxanthoma ElasticumUniversity Hospital, Angers
- RECRUITINGNCT06636344Impact of Optimized Recruitment and Follow-up of Patients with Pseudoxanthoma Elasticum (PXE)University Hospital, Angers
- RECRUITINGNCT07048106Progression Assessment of PXE-associated AlterationsUniversity Hospital, Bonn
- RECRUITINGPHASE2NCT06462547ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 DeficiencyInozyme Pharma
- RECRUITINGPHASE3NCT05832580The Prevention of Systemic Ectopic Mineralization in Pseudoxanthoma ElasticumUMC Utrecht
- RECRUITINGNANCT04868578PPI Supplementation to Fight ECtopIc Calcification in PXECentre Hospitalier Universitaire de Nice
- ACTIVE NOT RECRUITINGNCT05662085Progression Rate of Pseudoxanthoma Elasticum-associated Choroidal and Retinal DegenerationUniversity Hospital, Basel, Switzerland